JP2019514858A5 - - Google Patents

Download PDF

Info

Publication number
JP2019514858A5
JP2019514858A5 JP2018551440A JP2018551440A JP2019514858A5 JP 2019514858 A5 JP2019514858 A5 JP 2019514858A5 JP 2018551440 A JP2018551440 A JP 2018551440A JP 2018551440 A JP2018551440 A JP 2018551440A JP 2019514858 A5 JP2019514858 A5 JP 2019514858A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
weeks
antibody
patient
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018551440A
Other languages
English (en)
Japanese (ja)
Other versions
JP7468992B2 (ja
JP2019514858A (ja
JPWO2017172771A5 (enExample
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/024544 external-priority patent/WO2017172771A2/en
Publication of JP2019514858A publication Critical patent/JP2019514858A/ja
Publication of JP2019514858A5 publication Critical patent/JP2019514858A5/ja
Priority to JP2021153624A priority Critical patent/JP2022023053A/ja
Priority to JP2023136300A priority patent/JP2023162316A/ja
Publication of JPWO2017172771A5 publication Critical patent/JPWO2017172771A5/ja
Application granted granted Critical
Publication of JP7468992B2 publication Critical patent/JP7468992B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018551440A 2016-03-29 2017-03-28 抗il12及び/又は-23抗体の増加した間隔投与による乾癬の処置 Active JP7468992B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021153624A JP2022023053A (ja) 2016-03-29 2021-09-21 抗il12及び/又は-23抗体の増加した間隔投与による乾癬の処置
JP2023136300A JP2023162316A (ja) 2016-03-29 2023-08-24 抗il12及び/又は-23抗体の増加した間隔投与による乾癬の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662314697P 2016-03-29 2016-03-29
US62/314,697 2016-03-29
PCT/US2017/024544 WO2017172771A2 (en) 2016-03-29 2017-03-28 Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021153624A Division JP2022023053A (ja) 2016-03-29 2021-09-21 抗il12及び/又は-23抗体の増加した間隔投与による乾癬の処置

Publications (4)

Publication Number Publication Date
JP2019514858A JP2019514858A (ja) 2019-06-06
JP2019514858A5 true JP2019514858A5 (enExample) 2020-04-30
JPWO2017172771A5 JPWO2017172771A5 (enExample) 2024-02-07
JP7468992B2 JP7468992B2 (ja) 2024-04-16

Family

ID=58609978

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018551440A Active JP7468992B2 (ja) 2016-03-29 2017-03-28 抗il12及び/又は-23抗体の増加した間隔投与による乾癬の処置
JP2021153624A Withdrawn JP2022023053A (ja) 2016-03-29 2021-09-21 抗il12及び/又は-23抗体の増加した間隔投与による乾癬の処置
JP2023136300A Pending JP2023162316A (ja) 2016-03-29 2023-08-24 抗il12及び/又は-23抗体の増加した間隔投与による乾癬の処置

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021153624A Withdrawn JP2022023053A (ja) 2016-03-29 2021-09-21 抗il12及び/又は-23抗体の増加した間隔投与による乾癬の処置
JP2023136300A Pending JP2023162316A (ja) 2016-03-29 2023-08-24 抗il12及び/又は-23抗体の増加した間隔投与による乾癬の処置

Country Status (12)

Country Link
US (2) US10765724B2 (enExample)
EP (1) EP3436477A2 (enExample)
JP (3) JP7468992B2 (enExample)
KR (2) KR20180128471A (enExample)
CN (1) CN109071653A (enExample)
AU (1) AU2017241776B2 (enExample)
BR (1) BR112018069776A2 (enExample)
CA (1) CA3019164A1 (enExample)
EA (1) EA201892190A1 (enExample)
IL (1) IL261859B (enExample)
MA (1) MA44510A (enExample)
WO (1) WO2017172771A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180128471A (ko) * 2016-03-29 2018-12-03 얀센 바이오테크 인코포레이티드 항-il12 및/또는 항-il23 항체의 증가된 투여 간격을 사용한 건선의 치료
CN110603840B (zh) * 2017-05-02 2023-10-27 苹果公司 用于新无线电(nr)系统的间隙模式设计
CA3081343A1 (en) * 2017-11-06 2019-05-09 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
US20190269757A1 (en) 2018-03-05 2019-09-05 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
WO2019220412A2 (en) * 2018-05-18 2019-11-21 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
JP7660067B2 (ja) * 2019-03-14 2025-04-10 ヤンセン バイオテツク,インコーポレーテツド 抗il12/il23抗体組成物を生成するための製造方法
AU2020243588B2 (en) * 2019-03-18 2025-12-18 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-IL12/IL23 antibody
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
EP4017534A4 (en) * 2019-08-19 2023-12-27 Wayne State University IN VIVO IMMUNOIMAGING OF INTERLEUKIN-12
MX2022014430A (es) 2020-05-21 2023-02-22 Janssen Biotech Inc Método para tratar la enfermedad inflamatoria del intestino con una terapia de combinación de anticuerpos para il-23 y tnf alfa.
CN112255418B (zh) * 2020-10-20 2024-05-07 中国人民解放军军事科学院军事医学研究院 血浆蛋白组合在制备预测低剂量辐射照射剂量的产品中的应用
TW202321282A (zh) 2021-07-19 2023-06-01 美商再生元醫藥公司 Il12受體促效劑及其使用方法
CN121013860A (zh) 2023-01-13 2025-11-25 再生元制药公司 Il12受体激动剂及其使用方法
WO2025071366A1 (ko) * 2023-09-27 2025-04-03 삼성바이오에피스 주식회사 항-il-23 항체의 자가-완충 액상 제형
WO2025166063A1 (en) 2024-01-31 2025-08-07 Bluerock Therapeutics Lp Igfbp2 in cell culture

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US766886A (en) 1904-02-10 1904-08-09 Int Harvester Co Hay-rake.
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB2097032B (en) 1981-04-22 1984-09-19 Teron International Urban Dev A combined ceiling air and services distribution system mechanical chasse and structural roof member
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
DE229046T1 (de) 1985-03-30 1987-12-17 Marc Genf/Geneve Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US4766067A (en) 1985-05-31 1988-08-23 President And Fellows Of Harvard College Gene amplification
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US4921794A (en) 1987-01-14 1990-05-01 President And Fellows Of Harvard College T7 DNA polymerase
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
ATE114723T1 (de) 1987-03-02 1994-12-15 Enzon Lab Inc Organismus als träger für ''single chain antibody domain (scad)''.
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
US4939666A (en) 1987-09-02 1990-07-03 Genex Corporation Incremental macromolecule construction methods
JP2980626B2 (ja) 1988-01-11 1999-11-22 ゾーマ・コーポレーション ペクチン酸リアーゼのシグナル配列を含む新規プラスミドベクター
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5091310A (en) 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US5142033A (en) 1988-09-23 1992-08-25 Hoffmann-La Roche Inc. Structure-independent DNA amplification by the polymerase chain reaction
US5066584A (en) 1988-09-23 1991-11-19 Cetus Corporation Methods for generating single stranded dna by the polymerase chain reaction
US4987893A (en) 1988-10-12 1991-01-29 Rochal Industries, Inc. Conformable bandage and coating material
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
EP0441900B1 (en) 1988-11-10 1996-07-17 Genetics Institute, Inc. Natural killer stimulatory factor
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4994370A (en) 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
DE3909708A1 (de) 1989-03-23 1990-09-27 Boehringer Mannheim Gmbh Verfahren zur herstellung bispezifischer antikoerper
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2057923A1 (en) 1989-05-16 1990-11-17 William D. Huse Co-expression of heteromeric receptors
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2062795A1 (en) 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
DK0494955T3 (da) 1989-10-05 1998-10-26 Optein Inc Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
DE69034244T2 (de) 1989-12-22 2008-04-03 F. Hoffmann-La Roche Ag Zytotoxischer Lymphozyten-Reifefaktor 35kD Untereinheit und monoklonale Antikörper spezifisch dafür
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
TW212184B (enExample) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU8081491A (en) 1990-06-01 1991-12-31 Cetus Corporation Compositions and methods for identifying biologically active molecules
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
EP0547065B1 (en) 1990-06-29 2001-08-29 Large Scale Biology Corporation Melanin production by transformed microorganisms
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
WO1992005258A1 (en) 1990-09-20 1992-04-02 La Trobe University Gene encoding barley enzyme
ATE160379T1 (de) 1990-10-29 1997-12-15 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
JPH06508022A (ja) 1991-02-21 1994-09-14 ギリアド サイエンシズ,インコーポレイテッド 生体分子に特異的なアプタマーおよび生産方法
EP0575545B1 (en) 1991-03-15 2003-05-21 Amgen Inc. Pegylation of polypeptides
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
DE4207475A1 (de) 1992-03-10 1993-09-16 Goldwell Ag Mittel zum blondieren von menschlichen haaren und verfahren zu dessen herstellung
WO1994008038A1 (en) 1992-10-02 1994-04-14 Trustees Of Dartmouth College Bispecific reagents for redirected targeting of low density lipoprotein
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5770428A (en) 1993-02-17 1998-06-23 Wisconsin Alumni Research Foundation Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
DE4315127A1 (de) 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
CA2125763C (en) 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
DE4337197C1 (de) 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
SE9304060D0 (sv) 1993-12-06 1993-12-06 Bioinvent Int Ab Sätt att selektera specifika bakteriofager
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
DK0749325T3 (da) 1994-03-07 2002-10-07 Medarex Inc Bispecifikke molekyler med klinisk anvendelse
ZA95960B (en) 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
BR9507505A (pt) 1994-04-22 1997-09-02 Corixa Corp Molécula de dna isolada vetor de expressão recombinante célula hospedeira método para preparar um polipeptídeo que estimula uma resposta imunológica th1 em células mononucleares do sangue periférico obtidas a partir de um individuo infectado com leishmania polipeptídeo método para avaliar a capacidade de um paciente de gerar uma resposta imunológica método para melhorar uma resposta imunológica celular e/ou humoral a um antígeno de um paciente método para estimular a produção de anticorpos em um
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
JP3659261B2 (ja) 1994-10-20 2005-06-15 モルフォシス・アクチェンゲゼルシャフト 組換体タンパク質の多機能性複合体への標的化ヘテロ結合
US5549551A (en) 1994-12-22 1996-08-27 Advanced Cardiovascular Systems, Inc. Adjustable length balloon catheter
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
DE69621940T2 (de) 1995-08-18 2003-01-16 Morphosys Ag Protein-/(poly)peptidbibliotheken
US5853697A (en) 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
DE19624387C2 (de) 1996-06-19 1999-08-19 Hatz Motoren Kaltstartvorrichtung
DK0826695T3 (da) 1996-09-03 2002-04-15 Gsf Forschungszentrum Umwelt Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
AU6150498A (en) 1997-02-07 1998-08-26 Wistar Institute, The Methods and compositions for the inhibition of interleukin-12 production
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
CZ300758B6 (cs) 1997-09-29 2009-08-05 Nektar Therapeutics Práškovitý prípravek obsahující perforované mikrostruktury
PT1049717E (pt) 1998-01-23 2007-05-31 Hoffmann La Roche Anticorpos contra a il-12 humana.
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
CA2353520C (en) 1998-12-09 2006-04-25 Protein Design Labs, Inc. Animal model for psoriasis for the prevention and treatment of psoriasis in humans
NZ539776A (en) 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
NZ596723A (en) 1999-03-25 2013-07-26 Abbott Gmbh & Co Kg Human antibodies that bind human il-12 and methods for producing
AU7127600A (en) 1999-09-17 2001-04-17 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
CA2442801A1 (en) 2001-04-02 2002-10-10 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with gntiii
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
AU2003247411A1 (en) 2002-05-23 2003-12-12 Cognis Corporation NON-REVERTIBLE Beta-OXIDATION BLOCKED CANDIDA TROPICALIS
EA019476B9 (ru) 2005-12-29 2020-07-14 Янссен Байотек, Инк. АНТИТЕЛА ПРОТИВ IL-23p19 И ИХ ПРИМЕНЕНИЕ
CN101668531B (zh) * 2007-02-28 2014-05-07 默沙东公司 用于治疗免疫病症的联合治疗
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
JP5155355B2 (ja) 2010-04-07 2013-03-06 レノボ・シンガポール・プライベート・リミテッド 無線基地局の自律的な負荷調整が可能な無線端末装置
KR20140091038A (ko) * 2011-11-03 2014-07-18 톨러러 세러퓨틱스 인코포레이티드 T-세포 반응의 선택적 억제를 위한 항체 및 방법
HK1210937A1 (en) 2012-12-19 2016-05-13 波利化学公司 Use of pidotimod to treat psoriasis
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
EP3693007A1 (en) * 2013-03-15 2020-08-12 Amgen, Inc Methods for treating crohn's disease using an anti-il23 antibody
HK1219425A1 (zh) * 2013-03-15 2017-04-07 Amgen Inc. 使用抗il-23抗体治疗银屑病的方法
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
EP3033107A1 (en) * 2013-08-15 2016-06-22 Novartis AG Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
CN104530413B (zh) * 2014-10-01 2017-08-25 厦门赛诺邦格生物科技股份有限公司 一种多官能化h型聚乙二醇衍生物修饰的生物相关物质
KR20180128471A (ko) * 2016-03-29 2018-12-03 얀센 바이오테크 인코포레이티드 항-il12 및/또는 항-il23 항체의 증가된 투여 간격을 사용한 건선의 치료
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Similar Documents

Publication Publication Date Title
JP2019514858A5 (enExample)
JP6878524B2 (ja) Il−17抗体の医薬製品および安定した液体組成物
JP2020500152A5 (enExample)
JP2019517549A5 (enExample)
JP2020502261A5 (enExample)
JP7266108B2 (ja) 治療用抗体製剤
CN110475551A (zh) 使用短链脂肪酸治疗和预防疾病和障碍
JPWO2017172771A5 (enExample)
JP2017511793A5 (enExample)
JP2020535149A5 (enExample)
IL316408A (en) A safe and effective method for treating psoriasis with a specific anti-IL23 antibody
JP7792959B2 (ja) 持続放出パリペリドン注射可能製剤に関連する投与レジメン
JP7792409B2 (ja) 持続放出パリペリドン注射可能製剤に関連する投与レジメン
CN118178647A (zh) 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体
JP2016536327A5 (enExample)
RS65815B1 (sr) Režimi doziranja povezani sa formulacijama za injektovanje paliperidona sa produženim oslobađanjem
CA3113468A1 (en) Grapiprant unit dosage forms
JP2021152002A5 (enExample)
HRP20240703T1 (hr) Telmisartan za profilaksu ili liječenje hipertenzije kod mačaka
JP2021091608A5 (enExample)
Hsu et al. OP0025 Results from a multicenter, international, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy
EP3784243B1 (en) Methotrexate for use as a medicament
CN101287469A (zh) 5-(2-氯苯基)-1,2-二氢-7-氟-8-甲氧基-3-甲基-吡唑并[3,4-b][1,4]苯并二氮杂䓬的给药方案
JPWO2020128864A5 (enExample)
Cui et al. LB0008 SAP-001, A FIRST–IN-CLASS COMPOUND TARGETING A RENAL URATE TRANSPORTER, SHOWS POTENT SERUM URATE-LOWERING EFFECTS AND FAVORABLE SAFETY PROFILE IN A US PHASE 2b STUDY IN PATIENTS WITH REFRACTORY GOUT WITH OR WITHOUT PALPABLE TOPHI